GoodRx Holdings (GDRX) Accounts Payables (2019 - 2026)

GoodRx Holdings has disclosed Accounts Payables across 8 years of filings, most recently posting $14.5 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $14.5 million, down 4.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.5 million (down 4.8% YoY), and the FY2025 annual result was $19.4 million, up 37.26% from the prior year.
• Accounts Payables came in at $14.5 million for Q1 2026 at GoodRx Holdings, down from $19.4 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $36.3 million in Q4 2023 to a low of $6.8 million in Q2 2023.
• The 5-year median for Accounts Payables is $16.8 million (2022), against an average of $19.2 million.
• Across the five-year window, Accounts Payables surged 203.13% in 2023 and slumped 62.34% in 2024, its largest moves.
• GoodRx Holdings' Accounts Payables stood at $17.7 million in 2022, then jumped by 104.89% to $36.3 million in 2023, then slumped by 61.02% to $14.1 million in 2024, then surged by 37.26% to $19.4 million in 2025, then declined by 25.15% to $14.5 million in 2026.
• The last three Accounts Payables figures came in at $14.5 million (Q1 2026), $19.4 million (Q4 2025), and $28.7 million (Q3 2025), per Business Quant data.